M&T Bank Corp Raises Stock Holdings in Illumina, Inc. $ILMN

Key Points

• M&T Bank Corp increased its position in Illumina by 190.6% in Q4 to 24,806 shares, worth about $3.25 million.
• Illumina beat quarterly expectations with $1.35 EPS (vs. $1.26 est.) and $1.16B revenue (up 5%), set FY2026 guidance of 5.050–5.200 EPS, and carries a consensus analyst target of $129.69 with mixed ratings.
• Institutional investors own 89.42% of Illumina, while insider SVP Patricia Leckman sold 2,370 shares, reducing her stake by roughly 12.7%.

M&T Bank Corp increased its position in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 190.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 24,806 shares of the life sciences company's stock after acquiring an additional 16,269 shares during the period. M&T Bank Corp's holdings in Illumina were worth $3,254,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in ILMN. Empowered Funds LLC grew its position in Illumina by 113.7% during the 1st quarter. Empowered Funds LLC now owns 9,284 shares of the life sciences company's stock worth $737,000 after purchasing an additional 4,940 shares during the period. Sivia Capital Partners LLC acquired a new stake in Illumina during the 2nd quarter worth about $621,000. CW Advisors LLC acquired a new stake in Illumina during the 2nd quarter worth about $275,000. Marshall Wace LLP grew its position in Illumina by 49.0% during the 2nd quarter. Marshall Wace LLP now owns 59,645 shares of the life sciences company's stock worth $5,691,000 after purchasing an additional 19,618 shares during the period. Finally, Cresset Asset Management LLC grew its position in Illumina by 30.9% during the 2nd quarter. Cresset Asset Management LLC now owns 7,404 shares of the life sciences company's stock worth $706,000 after purchasing an additional 1,748 shares during the period. Hedge funds and other institutional investors own 89.42% of the company's stock.

Illumina Price Performance

NASDAQ:ILMN opened at $128.52 on Tuesday. Illumina, Inc. has a 52 week low of $73.86 and a 52 week high of $155.53. The company has a quick ratio of 1.72, a current ratio of 2.08 and a debt-to-equity ratio of 0.55. The stock has a market capitalization of $19.52 billion, a PE ratio of 23.58, a price-to-earnings-growth ratio of 2.45 and a beta of 1.49. The stock's 50-day moving average price is $125.33 and its 200-day moving average price is $126.24.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its earnings results on Thursday, February 5th. The life sciences company reported $1.35 EPS for the quarter, beating analysts' consensus estimates of $1.26 by $0.09. Illumina had a return on equity of 31.04% and a net margin of 19.57%.The firm had revenue of $1.16 billion for the quarter, compared to analysts' expectations of $1.10 billion. During the same period last year, the firm earned $0.95 EPS. The company's quarterly revenue was up 5.0% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. As a group, equities analysts expect that Illumina, Inc. will post 5.12 EPS for the current fiscal year.

Insider Activity at Illumina

In other news, SVP Patricia Leckman sold 2,370 shares of the firm's stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $116.18, for a total transaction of $275,346.60. Following the sale, the senior vice president directly owned 16,321 shares in the company, valued at $1,896,173.78. This trade represents a 12.68% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 2.90% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on ILMN shares. Guggenheim increased their price target on Illumina from $144.00 to $170.00 and gave the stock a "buy" rating in a research report on Monday, January 26th. TD Cowen reaffirmed a "hold" rating on shares of Illumina in a research report on Wednesday, January 7th. Canaccord Genuity Group increased their price target on Illumina from $130.00 to $150.00 and gave the stock a "hold" rating in a research report on Monday, January 26th. Robert W. Baird set a $137.00 price target on Illumina in a research report on Friday, February 6th. Finally, Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Illumina in a research report on Monday, December 29th. Six investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have given a Sell rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus target price of $129.69.

About Illumina

Illumina, Inc NASDAQ: ILMN is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company's product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.